Compare Merck & Co., Inc. (MRK) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Newegg Commerce Inc — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while Newegg Commerce Inc trades at $14.93 (market cap $315.87M). The key difference: Merck & Co., Inc. is far larger — about 1159.6× Newegg Commerce Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals.
| MRK | NEGG | |
|---|---|---|
Market Cap | $366.28B | $315.87M |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $92.74 |
52-Week Low | $77.60 | $12.87 |
Enterprise Value | $413.04B | $286.10M |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
NEGG trades at $15.17, down 0.98% on the day, with a bearish technical signal from moving averages but recent earnings beats showing improvement. The company reported Q2 2026 EPS of $0.11, beating expectations by $0.51, while revenue trends show stabilization after declines from 2022-2024. Valuation metrics include a P/E of 33.27 and P/S of 0.23, with improving profitability margins.
The outlook suggests cautious optimism as NEGG demonstrates operational improvement with four consecutive earnings beats and positive net income projected for 2026. Key risks include negative operating cash flow and competitive e-commerce pressures, while the single analyst coverage maintains a Buy rating with 100% consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
